A Placebo-Controlled Trial of Pioglitazone in Subjects with Nonalcoholic Steatohepatitis
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
BACKGROUND: No pharmacologic therapy has conclusively proved to be effective for the treatment of nonalcoholic steatohepatitis, which is characterized by insulin resistance, steatosis, and necroinflammation with or without centrilobular fibrosis. Pioglitazone is a thiazolidinedione that ameliorates insulin resistance and improves glucose and lipid metabolism in type 2 diabetes mellitus. METHODS: We randomly assigned 55 patients with impaired glucose tolerance or type 2 diabetes and liver biopsy-confirmed nonalcoholic steatohepatitis to 6 months of treatment with a hypocaloric diet (a reduction of 500 kcal per day in relation to the calculated daily intake required to maintain body weight) plus pioglitazone (45 mg daily) or a hypocaloric diet plus placebo. Before and after treatment, we assessed hepatic histologic features, hepatic fat content by means of magnetic resonance spectroscopy, and glucose turnover during an oral glucose tolerance test ([14C]glucose given with the oral glucose load and [3H]glucose given by intravenous infusion). RESULTS: Diet plus pioglitazone, as compared with diet plus placebo, improved glycemic control and glucose tolerance (P<0.001), normalized liver aminotransferase levels as it decreased plasma aspartate aminotransferase levels (by 40% vs. 21%, P=0.04), decreased alanine aminotransferase levels (by 58% vs. 34%, P<0.001), decreased hepatic fat content (by 54% vs. 0%, P<0.001), and increased hepatic insulin sensitivity (by 48% vs. 14%, P=0.008). Administration of pioglitazone, as compared with placebo, was associated with improvement in histologic findings with regard to steatosis (P=0.003), ballooning necrosis (P=0.02), and inflammation (P=0.008). Subjects in the pioglitazone group had a greater reduction in necroinflammation (85% vs. 38%, P=0.001), but the reduction in fibrosis did not differ significantly from that in the placebo group (P=0.08). Fatigue and mild lower-extremity edema developed in one subject who received pioglitazone; no other adverse events were observed. CONCLUSIONS: In this proof-of-concept study, the administration of pioglitazone led to metabolic and histologic improvement in subjects with nonalcoholic steatohepatitis. Larger controlled trials of longer duration are warranted to assess the long-term clinical benefit of pioglitazone. (ClinicalTrials.gov number, NCT00227110 [ClinicalTrials.gov] .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Significant improvements were observed in hepatic steatosis, hepatocellular ballooning, necrosis, and inflammation; however, fibrosis reduction did not reach statistical significance compared with placebo.”
From Strategies to promote liver fibrosis amelioration with involvement of restorative macrophages (2026) · cites this paper as [202]
In the citing paper
“Accruing randomized clinical trial data suggest that pioglitazone, GLP-1 RA, and a dual GIP and GLP-1 RA have potential benefits in terms of decreasing hepatic steatosis and in the resolution of MASH without worsening of fibrosis in individuals with biopsy-proven MASH or those at higher risk of clinically significant liver fibrosis identified with noninvasive tests (146-153).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [146]
In the citing paper
“Treatment with exenatide reduced liver steatosis [109,146,150] and when added to pioglitazone, an oral hypoglycemic and insulin sensitizing drug approved for the treatment of T2D that acts on nuclear peroxisome proliferator activated receptor-gamma (PPAR-γ) [147], potentiated the known action of pioglitazone in reducing hepatic fat [92].”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [92]
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Role of AMP-Activated Protein Kinase in Mechanism of Metformin Action
Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13505 · Cited by 5,652
Matsuda, M., & DeFronzo, R. A. (1999) · Diabetes Care · doi:10.2337/diacare.22.9.1462 · Cited by 5,621
Self-citationYamauchi, T., Kamon, J., Minokoshi, Y., Ito, Y., Waki, H., Uchida, S., Yamashita, S., Noda, M., Kita, S., Ueki, K., et al. (2002) · Nature Medicine · doi:10.1038/nm788 · Cited by 4,238
Prevalence of Hepatic Steatosis in An Urban Population in the United States: Impact of Ethnicity
Browning, J. D., Szczepaniak, L. S., Dobbins, R., Nuremberg, P., Horton, J. D., Cohen, J. C., Grundy, S. M., & Hobbs, H. H. (2004) · Hepatology · doi:10.1002/hep.20466 · Cited by 3,664
Sampling Variability of Liver Biopsy in Nonalcoholic Fatty Liver Disease
Ratziu, V., Charlotte, F., Heurtier, A., Gombert, S., Giral, P., Bruckert, E., Grimaldi, A., Capron, F., & Poynard, T. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.03.084 · Cited by 2,106
Molecular mediators of hepatic steatosis and liver injury
Browning, J. D., & Horton, J. D. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200422422 · Cited by 1,772
Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease
Samuel, V. T., Liu, Z.-X., Qu, X., Elder, B. D., Bilz, S., Befroy, D., Romanelli, A. J., & Shulman, G. I. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m313478200 · Cited by 1,322
Xu, A., Wang, Y., Keshaw, H., Xu, L. Y., Lam, K. S. L., & Cooper, G. J. S. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200317797 · Cited by 1,298
Xu, A., Wang, Y., Keshaw, H., Xu, L. Y., Lam, K. S. L., & Cooper, G. J. S. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17797 · Cited by 1,296
Research works printed but not linked: 3
- 10.1111/j.1572-0241.2003.08699.x · doi:10.1111/j.1572-0241.2003.08699.x · Paper page
- 10.1210/jc.87.6.2784 · doi:10.1210/jc.87.6.2784 · Paper page
- 10.1172/JCI22422 · DOI · Paper page
Cited by
Items 901–1,000 of 1,003
Tian, Y.-F., He, C.-T., Chen, Y.-T., & Hsieh, P.-S. (2013) · World Journal of Gastroenterology · doi:10.3748/wjg.v19.i18.2761 · Cited by 34
Seeff, L. B., & Fontana, R. J. (2011) · Wiley eBooks · doi:10.1002/9781444341294.ch24 · Cited by 29
Albert, S. G., & Wood, E. M. (2024) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2024.108777 · Cited by 36
Suresh, M. G., Mohamed, S., Geetha, H. S., Prabhu, S., Trivedi, N., Ng, Z. C., Mehta, P. D., Brar, A. S., Sohal, A., Goyal, M. K., et al. (2026) · World Journal of Diabetes · doi:10.4239/wjd.v17.i2.113149 · Cited by 36
Pisano, G., Fracanzani, A. L., Caccamo, L., Donato, M. F., & Fargion, S. R. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i40.8869 · Cited by 31
Current management of non-alcoholic fatty liver disease
Lisboa, Q. C., COSTA, S. M. F., & Couto, C. A. (2016) · Revista da Associação Médica Brasileira · doi:10.1590/1806-9282.62.09.872 · Cited by 32
Liu, H.-J., Cao, S., Wen, B., Han, X., Li, Y., Li, S., Li, J., & Zhang, L. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108065 · Cited by 36
Luo, Q., Wei, R., Cai, Y., Zhao, Q., Liu, Y., & Liu, W. J. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.793203 · Cited by 28
“First, there was a small number of open-label studies we could include (17, 26, 30, 31).”
BackgroundNishi, T., Babazono, A., Maeda, T., Imatoh, T., & Une, H. (2014) · Journal of Diabetes Investigation · doi:10.1111/jdi.12290 · Cited by 32
Nonalcoholic Fatty Liver Disease and Insulin Resistance in Youth
Bloomgarden, Z. T. (2007) · Diabetes Care · doi:10.2337/dc07-zb06 · Cited by 31
Concentration‐dependent response to pioglitazone in nonalcoholic steatohepatitis
Kawaguchi‐Suzuki, M., Bril, F., Kalavalapalli, S., Cusi, K. J., & Frye, R. F. (2017) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14111 · Cited by 28
Self-citationTreatment options for nonalcoholic steatohepatitis - a safety evaluation
Issa, D., Wattacheril, J. J., & Sanyal, A. J. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1343299 · Cited by 30
“Thiazolidinediones such as pioglitazone and rosiglitazone are synthetic PPAR-γ agonists and insulin sensitizers which have also shown positive outcomes in patients with NASH [57,58].”
BackgroundReview article: nonalcoholic fatty liver disease and hepatitis C virus – partners in crime
BLONSKY, J. J., & Harrison, S. A. (2008) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2008.03672.x · Cited by 30
Self-citationMisra, A., Kumar, A., Kuchay, M. S., Ghosh, A., Gulati, S., Choudhary, N. S., Dutta, D., Sharma, P., Vikram, N. K., Rastogi, A., et al. (2025) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2025.103209 · Cited by 28
Kanwal, F., Bril, F., Wong, V. W., Adams, L. A., Pfotenhauer, K. M., SKOLNIK, N., Wright, E. E., Eckel, R. H., Noureddin, M., Loomba, R. S., et al. (2026) · Gastroenterology · doi:10.1053/j.gastro.2026.01.047 · Cited by 47
Measuring Visceral and Hepatic Fat in Clinical Practice and Clinical Research
Naboush, A., & Hamdy, O. (2013) · Endocrine Practice · doi:10.4158/ep12331.or · Cited by 30
Pre-and-post transplant considerations in patients with nonalcoholic fatty liver disease
Khullar, V., Dolganiuc, A., & Firpi, R. J. (2014) · World Journal of Transplantation · doi:10.5500/wjt.v4.i2.81 · Cited by 27
Khavasi, N., Somi, M. H., Khadem, E., Faramarzi, E., Ayati, M. H., Fazljou, S. M. B., & Torbati, M. (2017) · Advanced Pharmaceutical Bulletin · doi:10.15171/apb.2017.077 · Cited by 29
Current and Emerging Therapies for Non-alcoholic Fatty Liver Disease
Patel, S. S., & Siddiqui, M. S. (2018) · Drugs · doi:10.1007/s40265-018-1040-1 · Cited by 29
Huan, Y., Pan, X., Peng, J., Jia, C., Sun, S., Bai, G., Wang, X., Zhou, T., Li, R., Liu, S., et al. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13843 · Cited by 29
Fibrosis progression rate in a systematic review of placebo‐treated nonalcoholic steatohepatitis
Roskilly, A., Hicks, A., Taylor, E., Jones, R. L., Parker, R., & Rowe, I. A. C. (2020) · Liver International · doi:10.1111/liv.14749 · Cited by 29
Current, emerging, and potential therapies for non-alcoholic steatohepatitis
Yang, Z. L., & Wang, L. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1152042 · Cited by 32
“Pioglitazone (a synthetic ligand of PPARγ) which is used clinically for the treatment of type 2 diabetes mellitus (T2DM) mitigates steatosis, inflammation, and fibrosis in subjects with NASH (Belfort et al., 2006; Aithal et al., 2008); however, it increases the patient’s weight and risk of bladder cancer (Sanyal et al.”
BackgroundKim, M.-S., Lee, K., Iseli, T. J., Hoy, A. J., George, J., Grewal, T., & Roufogalis, B. D. (2013) · Liver International · doi:10.1111/liv.12287 · Cited by 29
“Indeed, the only drug to show any promise for the treatment of NASH is the AMPK activating TZD, pioglitazone (28, 29).”
BackgroundZhou, M., Xu, A., Lam, K. S. L., Tam, P. K. H., Che, C., Chan, L., Lee, I., Wu, D., & Wang, Y. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.05.034 · Cited by 29
Hepatic Steatosis and Steatohepatitis: Are they Really Two Distinct Entities?
Fielding, C. M., & Angulo, P. (2014) · Current Hepatology Reports · doi:10.1007/s11901-014-0227-5 · Cited by 28
Taira, S.-I., Shimabukuro, M., Higa, M., Yabiku, K., Kozuka, C., Ueda, R., Sunagawa, S., Ohshiro, Y., Doi, M., Nanba, T., et al. (2013) · Internal Medicine · doi:10.2169/internalmedicine.52.0521 · Cited by 30
“These results are consistent with those of a previous study showing that the administration of Pioglitazone leads to improvement of hepatic insulin sensitivity and attenuation of liver lipid deposition in patients with nonalcoholic steatohepatitis (25).”
ResultMerat, S., Yarahmadi, S., Tahaghoghi, S., Alizadeh, Z., Sedighi, N., Mansournia, N., Ghorbani, A., & Malekzadeh, R. (2009) · Middle East Journal of Digestive Diseases · Cited by 27
Gharaibeh, N. E., Rahhal, M.-N., Rahimi, L., & Ismail‐Beigi, F. (2019) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s212715 · Cited by 31
Brunt, E. M., Neuschwander‐Tetri, B. A., & Burt, A. D. (2011) · Elsevier eBooks · doi:10.1016/b978-0-7020-3398-8.00006-4 · Cited by 29
Data on Adiponectin from 2010 to 2020: Therapeutic Target and Prognostic Factor for Liver Diseases?
Heydari, M., Cornide‐Petronio, M. E., Jiménez‐Castro, M. B., & Peralta, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155242 · Cited by 29
Sutinen, J. (2008) · PPAR Research · doi:10.1155/2009/373524 · Cited by 28
Thomas, E. L., Potter, E. L., Tosi, I., Fitzpatrick, J. A., Hamilton, G., Amber, V., Hughes, R. I., North, C., Holvoet, P., Seed, M., et al. (2007) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2007.03.043 · Cited by 28
Konings, L. A. M., Matute, L. M., Boeren, A. M. P., van de Luitgaarden, I. A. T., Dirksmeier-Harinck, F., de Knegt, R. J., Tushuizen, M. E., Grobbee, D. E., Holleboom, A. G., & Cabezas, M. C. (2025) · European Journal of Clinical Investigation · doi:10.1111/eci.70003 · Cited by 34
Management of nonalcoholic fatty liver disease in the Middle East
Sanai, F. M., Abaalkhail, F. A., Hasan, F. A., Farooqi, M. H., Alnahdi, N., & Younossi, Z. M. (2020) · World Journal of Gastroenterology · doi:10.3748/wjg.v26.i25.3528 · Cited by 29
Amirinejad, A., Totmaj, A. S., Mardali, F., Hekmatdoost, A., Emamat, H., Safa, M., & Shidfar, F. (2021) · BMC Complementary Medicine and Therapies · doi:10.1186/s12906-021-03396-x · Cited by 28
Grattagliano, I., Ciaula, A. D., Baj, J., Molina‐Molina, E., Shanmugam, H., Garruti, G., Wang, D. Q. ‐., & Portincasa, P. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1433-4_12 · Cited by 30
Non-alcoholic fatty liver disease: Current therapeutic options
Majumdar, A., Verbeek, J., & Tsochatzis, E. A. (2021) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2021.09.007 · Cited by 28
Cao, Y., Yue, S.-S., Wang, A.-Y., Xu, L., Hu, Y., Qiao, X., Wu, T., Ye, M., Wu, Y., & Qi, R. (2022) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2022.115146 · Cited by 29
Esteghamati, A., Afarideh, M., Feyzi, S., Noshad, S., & Nakhjavani, M. (2014) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2014.09.009 · Cited by 27
Evidence-Based Efficacy of Kampo Formulas in a Model of Non Alcoholic Fatty Liver
Fujimoto, M., Tsuneyama, K., Kainuma, M., SEKIYA, N., Goto, H., Takano, Y., TERASAWA, K., Selmi, C. F., Gershwin, M. E., & Shimada, Y. (2008) · Experimental Biology and Medicine · doi:10.3181/0707-rm-207 · Cited by 26
“We can only hypothesize that increased blood glucose levels and body fat mass might play a role (12, 41) or that new interactions between metabolic and inflammatory pathways should be identified, similar to what was reported in autoimmune diseases (42, 43).”
BackgroundResultArrese, M. A. (2008) · Hepatology · doi:10.1002/hep.22783 · Cited by 26
Dongiovanni, P., & Valenti, L. V. C. (2013) · PPAR Research · doi:10.1155/2013/452061 · Cited by 27
“However, also the thiazolidinediones (TZDs), a class of insulin sensitizers that are approved for the treatment of type 2 diabetes and have been shown to decrease steatosis in patients with NASH [39, 40], function as high affinity PPARγ agonists.”
Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: The Hidden Epidemic
Ismail, M. H. (2011) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e3182018598 · Cited by 30
Thiazolidinediones for the Treatment in NASH: Sustained Benefit After Drug Discontinuation?
Argo, C. K., Iezzoni, J. C., Al‐Osaimi, A. M. S., & Caldwell, S. H. (2009) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e31818f4fc2 · Cited by 26
Bathula, C., Tripathi, S., Srinivasan, R., Jha, K. K., Ganguli, A., Chakrabarti, G., Singh, S., Munshi, P., & Sen, S. (2016) · Organic & Biomolecular Chemistry · doi:10.1039/c6ob01257d · Cited by 26
Rimonabant as a novel therapeutic option for nonalcoholic steatohepatitis
Banasch, M., Goetze, O., Schmidt, W. E., & Meier, J. J. (2007) · Liver International · doi:10.1111/j.1478-3231.2007.01555.x · Cited by 26
“and, more recently, the thiazolidinediones (12).”
Drug treatment for metabolic dysfunction-associated steatotic liver disease: Progress and direction
Zhou, D., & Fan, J. (2024) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003355 · Cited by 30
HFpEF and MASLD: converging mechanisms and clinical implications
Capone, F., Häseli, S. P., Liu, L., Strocchi, S., Langenberg, C., Lusis, A. J., Pietzner, M., Muoio, D. M., Rider, O. J., Raman, B., et al. (2026) · Nature Reviews Cardiology · doi:10.1038/s41569-026-01257-z · Cited by 37
“Nevertheless, large RCTs specifically evaluating the effects of vitamin E supplementation in HFpEF are lacking.”
InfluentialState of the art: treatment of nonalcoholic steatohepatitis
Pearlman, M. Y., & Loomba, R. S. (2014) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000060 · Cited by 27
Nishimiya, N., Tajima, K., Imajo, K., Kameda, A., Yoshida, E., Togashi, Y., Aoki, K., Inoue, T., Nakajima, A., Utsunomiya, D., et al. (2021) · Internal Medicine · doi:10.2169/internalmedicine.7134-21 · Cited by 27
Portillo-Sánchez, P., Yavuz, S., Bril, F., & Cusi, K. J. (2014) · Current Hepatology Reports · doi:10.1007/s11901-014-0229-3 · Cited by 26
Self-citationPioglitazone and mechanisms of CV protection
Erdmann, E., & Wilcox, R. G. (2009) · QJM · doi:10.1093/qjmed/hcp168 · Cited by 26
“It remains unclear whether the ability of pioglitazone to reduce liver fat and markers of fatty liver disease in patients with type 2 diabetes or non alcoholic steatohepatitis is relevant to its effects on atherosclerosis and CV events.(5,129,132,133) A recent study suggests that pioglitazone may reduce myocardial fat…”
BackgroundClinical physiology of NAFLD: a critical overview of pathogenesis and treatment
Lonardo, A., Caldwell, S. H., & Loria, P. (2010) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.10.5 · Cited by 25
Emerging drugs for non-alcoholic fatty liver disease
Federico, A., Niosi, M., Blanco, C. D. V., & Loguercio, C. (2008) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.13.1.145 · Cited by 27
“[73] evaluated the effect of a hypocaloric diet plus pioglitazone or placebo on liver damage in patients with type 2 diabetes and obesity.”
BackgroundCheong, H., Lee, S. S., Lee, J. S., Kim, J., Kim, S. W., & Lee, W. J. (2014) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.24674 · Cited by 27
Vonghia, L., & Francque, S. (2015) · World Journal of Hepatology · doi:10.4254/wjh.v7.i15.1905 · Cited by 27
Rana, H., Yadav, S. S., Reddy, H. D., Singhal, S., Singh, D. K., & Usman, K. (2016) · JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH · doi:10.7860/jcdr/2016/19887.8336 · Cited by 25
Steato-Score: Non-Invasive Quantitative Assessment of Liver Fat by Ultrasound Imaging
Lascio, N. D., Avigo, C., Salvati, A., Martini, N., Ragucci, M., Monti, S., Prinster, A., Chiappino, D., Mancini, M., D'Elia, D., et al. (2018) · Ultrasound in Medicine & Biology · doi:10.1016/j.ultrasmedbio.2018.03.011 · Cited by 25
Posttransplant diabetes mellitus: recent developments in pharmacological management of hyperglycemia
Munoz Pena, J. M., & Cusi, K. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad395 · Cited by 24
Self-citationHepatic mitochondrial reductive stress in the pathogenesis and treatment of steatotic liver disease
Jokinen, M. J., & Luukkonen, P. K. (2024) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2024.02.003 · Cited by 27
Raschi, E., Mazzotti, A., Poluzzi, E., Ponti, F. D., & Marchesini, G. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1531126 · Cited by 30
Takaki, A., Kawano, S., Uchida, D., Takahara, M., Hiraoka, S., & Okada, H. (2019) · Cancers · doi:10.3390/cancers11020213 · Cited by 26
“A six-month randomized study of pioglitazone revealed a histopathological reduction in liver necroinflammation with no reduction in fibrosis [124].”
BackgroundJiang, C., Wang, Y., Jin, Q., Zhang, D., Gao, M. Q., Yao, N., Yin, Z., Zhang, J., & Ma, S. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00811 · Cited by 24
Emerging and Established Therapeutic Approaches for Nonalcoholic Fatty Liver Disease
Brown, E. E., Hydes, T., Hamid, A., & Cuthbertson, D. J. (2021) · Clinical Therapeutics · doi:10.1016/j.clinthera.2021.07.013 · Cited by 31
Role of ER stress inhibitors in the management of diabetes
Krishna Prasad, M., Mohandas, S., & Ramkumar, K. M. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.174893 · Cited by 30
Ndakotsu, A. K., & Vivekanandan, G. (2022) · Cureus · doi:10.7759/cureus.25380 · Cited by 28
“found a modest weight gain and an increase in body fat in the pioglitazone group [21].”
BackgroundMethodInfluentialAn, J., & Sohn, J. H. (2022) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0437 · Cited by 25
“0437 (30 or 45 mg/day) showed more histological improvement in NASH than those who received placebo.(12,19,20) Cusi et al.”
BackgroundNonalcoholic fatty liver disease from a primary care perspective
Clark, J. M., Cryer, D. R. H., Morton, M., & Shubrook, J. H. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15016 · Cited by 27
Moriya, T., Kitamori, K., Naito, H., Yanagiba, Y., Ito, Y., Yamagishi, N., Tamada, H., Jia, X., Tsuchikura, S., Ikeda, K., et al. (2012) · Environmental Health and Preventive Medicine · doi:10.1007/s12199-012-0273-y · Cited by 25
“In addition, despite a collapse in homeostatic fatty acid oxidation and energy metabolism functions due to decreasing levels of PPARa, PH, MCAD, AMPKa1/2, and p-AMPKa proteins [20, 48, 49], hepatic triglyceride in the HFC-diet group did not accumulate at 16 weeks.”
BackgroundRecomendaciones para el tratamiento farmacológico de la hiperglucemia en la diabetes tipo 2
Torre, E. L. M., Tejedor, F. J. L., Menéndez, S. A., Núñez-Cortés, J. M., Garcia, A. A., Puig‐Domingo, M., Soláns, J. R. G., Guisasola, F. Á., Alegría, J. G., Bravo, J. J. M., et al. (2011) · Atención Primaria · doi:10.1016/j.aprim.2010.07.012 · Cited by 30
Siddiqui, F. A., Sher, N., Zubair, A., Shamshad, H., Shafi, N., & Mirza, A. Z. (2013) · Analytical Methods · doi:10.1039/c3ay40884a · Cited by 24
Metabolic syndrome and non-alcoholic fatty liver disease in liver surgery: The new scourges?
Cauchy, F., Fuks, D., Bian, A. Z. L., Belghiti, J., & Costi, R. (2014) · World Journal of Hepatology · doi:10.4254/wjh.v6.i5.306 · Cited by 25
Treatment of nonalcoholic steatohepatitis with colestimide
Taniai, M., Hashimoto, E., Tobari, M., Yatsuji, S., Haruta, I., Tokushige, K., & Shiratori, K. (2009) · Hepatology Research · doi:10.1111/j.1872-034x.2009.00507.x · Cited by 23
Association of Non-alcoholic Fatty Liver Disease with Conduction Defects on Electrocardiogram
Mangi, M. A., Minhas, A. M. K., Rehman, H., Pathan, F., Hong, L., & Beidas, S. (2017) · Cureus · doi:10.7759/cureus.1107 · Cited by 27
Prasoppokakorn, T., Pitisuttithum, P., & Treeprasertsuk, S. (2021) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2021.00189 · Cited by 27
Pioglitazone: update on an oral antidiabetic drug with antiatherosclerotic effects
Pfützner, A., Weber, M. M., & Forst, T. M. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.12.1985 · Cited by 26
“The authors concluded that the administration of pioglitazone led to metabolic and histologic improvement in subjects with non-alcoholic steatohepatitis [57] .”
BackgroundIto, D., Shimizu, S., Haisa, A., Yanagisawa, S., Inoue, K., Saito, D., Sumita, T., Yanagisawa, M., Uchida, Y., Inukai, K., et al. (2024) · Journal of Diabetes Investigation · doi:10.1111/jdi.14246 · Cited by 27
“Although previous studies have reported that pioglitazone histologically improves MASLD/MASH 30 , much of the evidence has been based primarily on the effect of pioglitazone at a dose of 45 mg/day in Western populations.”
ResultInfluentialGoto, H., & Takamura, T. (2025) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes25017 · Cited by 30
“56,57 Those studies reported significant improvements in steatosis, inflammation, and ballooning degeneration, compared with placebo.”
Prevention of in vitro hepatic stellate cells activation by the adenosine derivative compound IFC305
Velasco-Loyden, G., Pérez‐Carreón, J. I., Agüero, J. F. C., Romero, P. C., Vidrio, S., Martínez-Pérez, L., Yañez-Maldonado, L., Hernández-Muñoz, R. E., Macías‐Silva, M., & de Sánchez, V. C. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.08.017 · Cited by 22
The latest idea in NAFLD/NASH pathogenesis
Ono, M., Okamoto, N., & Saibara, T. (2010) · Clinical Journal of Gastroenterology · doi:10.1007/s12328-010-0182-9 · Cited by 27
“The results of a randomized controlled study were reported [23, 24].”
BackgroundLestari, K., Hwang, J., Kariadi, S. H. K. S., Wijaya, A., Ahmad, T. H., Subarnas, A., Supriyatna, & Muchtaridi, M. (2012) · Medical and Health Science Journal · doi:10.15208/mhsj.2012.37 · Cited by 23
Ipsen, E. Ø., Madsen, K. S., Chi, Y., Pedersen-Bjergaard, U., Richter, B., Metzendorf, M.-I., & Hemmingsen, B. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013516.pub2 · Cited by 23
Dalem, J. D. R.-V., Driessen, J. H. M., Burden, A. M., Stehouwer, C. D. A., Klungel, O. H., de Vries, F., & Brouwers, M. C. G. J. (2021) · Hepatology · doi:10.1002/hep.32012 · Cited by 25
“Previous studies have investigated the association between TZDs and the development or resolution of NAFLD,(4-6, 20-22) including RCTs that used liver biopsies and a maximum follow-up of 2 years.”
BackgroundInfluentialChaudhary, S. P., Reyes, S., Chase, M. L., Govindan, A., Zhao, L., Luther, J., Bhan, I., Bethea, E. D., Franses, J. W., Walsh, E. P., et al. (2023) · The Oncologist · doi:10.1093/oncolo/oyac251 · Cited by 25
Cheng, P., Chen, W., Hou, C. J., Lin, C., Chang, M., Wang, C., Chang, W., Wang, C., Lin, C., Hung, C., et al. (2023) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2023.0315 · Cited by 29
Review of current and new drugs for the treatment of metabolic-associated fatty liver disease
Gish, R. G., Fan, J., Dossaji, Z., Fichez, J., Laeeq, T., Chun, M. J., & Boursier, J. (2024) · Hepatology International · doi:10.1007/s12072-024-10698-y · Cited by 26
Prevention and treatment of nonalcoholic fatty liver disease
Targher, G., Bellis, A., Fornengo, P., Ciaravella, M. F., Pichiri, I., Perin, P. C., Trimarco, B., & Marchesini, G. (2010) · Digestive and Liver Disease · doi:10.1016/j.dld.2010.02.004 · Cited by 27
“[69] Belfort R, Harrison SA, Brown K, et al.”
BackgroundRole of APN and TNF-α in type 2 diabetes mellitus complicated by nonalcoholic fatty liver disease
Lin, X., Zhang, Z., chen, J., Xu, Y., Ye, H. R., Cui, J.-S., Fang, Y. H., Jin, Y., Zhu, D., & Yuan, L. (2015) · Genetics and Molecular Research · doi:10.4238/2015.april.10.1 · Cited by 23
Insulin resistance and lipid disorders
Miccoli, R., Keyzer, D. D., Penno, D. G., & Prato, D. S. D. (2008) · Future Lipidology · doi:10.2217/17460875.3.6.651 · Cited by 32
Effect of fibrate treatment on liver function tests in patients with the metabolic syndrome
Gandhi, N., Lenton, R., Bhartia, M., Abbas, A., Raju, J., & Ramachandran, S. (2014) · SpringerPlus · doi:10.1186/2193-1801-3-14 · Cited by 25
Nonalcoholic Fatty Liver Disease
Gawrieh, S. (2016) · Springer eBooks · doi:10.1007/978-3-319-30103-7_14 · Cited by 25
Uchida, D., Takaki, A., Adachi, T., & Okada, H. (2018) · Nutrients · doi:10.3390/nu10080977 · Cited by 25
“A six-month randomized study of pioglitazone revealed a reduction in necroinflammation of liver histopathology with no reduction in fibrosis [68].”
BackgroundThe Future of Nonalcoholic Fatty Liver Disease Treatment
Mazhar, K. (2018) · Medical Clinics of North America · doi:10.1016/j.mcna.2018.08.005 · Cited by 27
Liver‐related long‐term outcomes of thiazolidinedione use in persons with type 2 diabetes
Yen, F., Yang, Y., Hwu, C., Wei, J. C., Huang, Y., Hou, M., & Hsu, C. (2020) · Liver International · doi:10.1111/liv.14385 · Cited by 25
The TONIC trial: A step forward in treating pediatric nonalcoholic fatty liver disease
Alkhouri, N., Feldstein, A. E., Groszmann, R. J., Iwakiri, Y., & Taddei, T. H. (2012) · Hepatology · doi:10.1002/hep.24767 · Cited by 25
“The beneficial antifibrotic effect of MIF in a mouse model of liver fibrosis demonstrated in this study by Heinrichs et al.(10) suggests that MIF is a novel target for treatment of chronic liver disease.”
BackgroundInfluentialReview: Advances in the treatment of nonalcoholic fatty liver disease
Mehta, S. R. (2010) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018810379587 · Cited by 25
“Pioglitazone, a TZD with weak PPAR-a activity, has been shown to improve both liver enzyme levels and liver histology in patients with NAFLD [Aithal et al. 2008; Belfort et al. 2006].”
BackgroundResultLiver dysfunction in paediatric obesity: a randomized, controlled trial of metformin
Freemark, M. (2007) · Acta Paediatrica · doi:10.1111/j.1651-2227.2007.00429.x · Cited by 23
“For example, a hypocaloric diet reduced serum ALT concentrations and hepatic inflammation in adults with impaired glucose tolerance (IGT) or type 2 diabetes, but had no effect on hepatic fat content or hepatocellular necrosis or fibrosis (23).”
Backgroundİdilman, İ. S., Keskın, O., Elhan, A. H., Idılman, R., & Karçaaltıncaba, M. (2014) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365521.2014.894118 · Cited by 24
Cassidy, F. H., Chavez, A. D., Schlang, A. M., Hassanein, T., Gamst, A. C., Wolfson, T. J., & Sirlin, C. B. (2007) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.21066 · Cited by 22
“In patients with fibrosis secondary to steatohepatitis, behavior modification is important and several experimental therapies are now under investigation (28).”
BackgroundSt. Rose, K., Yan, J., Xu, F., Williams, J., Dweck, V., Saxena, D., Schwabe, R. F., & Caviglia, J. M. (2022) · Hepatology Communications · doi:10.1002/hep4.2035 · Cited by 14
Metadata
- Authors
- Belfort, R., Harrison, S. A., Brown, K., Darland, C., Finch, J., Hardies, J., Balas, B., Gastaldelli, A., Tio, F., Pulcini, J., Berria, R., Ma, J. Z., Dwivedi, S., Havranek, R., Fincke, C., DeFronzo, R., Bannayan, G. A., Schenker, S., & Cusi, K.
- Affiliations
- The University of Texas at San Antonio Health Science Center (US)
- Brooke Army Medical Center (US)
- South Texas Veterans Health Care System (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-11-30
- Volume
- 355
- Issue
- 22
- Pages
- 2297-2307
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2103156933
- Cited by
- 1,827
- References
- 38
- Citations by year
- 2026: 44 · 2025: 73 · 2024: 83 · 2023: 78 · 2022: 84 · 2021: 93 · 2020: 73 · 2019: 74 · 2018: 70 · 2017: 93 · 2016: 98 · 2015: 106 · 2014: 92 · 2013: 87 · 2012: 85
- FWCI
- 91.90
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- INFM-OAR (INFN Catania) (submittedVersion, other-oa)
- Funders
- National Center for Research Resources (M01RR01346, M01RR001346)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Keywords
- alcoholic steatohepatitis, thiazolidinediones, insulin resistance, hypocaloric diet, hepatic steatosis, hepatic insulin sensitivity, necroinflammation, liver fibrosis, glucose tolerance, type 2 diabetes, impaired glucose tolerance, hepatic aminotransferases, drug safety, adverse effects
- MeSH terms
- Pioglitazone, Blood Glucose, Combined Modality Therapy, Diabetes Mellitus, Type 2, Double-Blind Method, Fatty Liver, Female, Hepatitis, Humans, Hypoglycemic Agents, Insulin, Insulin Resistance, Liver, Liver Cirrhosis, Male, Middle Aged, Necrosis, Glucose Intolerance, Caloric Restriction, Thiazolidinediones
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.